Nowadays, anyone who falls ill receives extensive treatment from a wide range of qualified medical professionals: doctors, therapists, nurses – and soon also artificial intelligence? That at least is the goal of Clinomic GmbH: to serve as an interface between medical professionals and the database. Through the unique combination of translational medical research, data science and computational intelligence, Clinomic develops medical algorithms based on state-of-the-art technology and artificial intelligence: The result is Mona, the intelligent assistance system for intensive care units. The smart assistant supports nurses and doctors in the optimal treatment of their patients.

After many years of successful cooperation between RWTH Aachen University and Uniklinik RWTH Aachen in the disciplines of engineering, electrical engineering and medical sciences, Clinomic GmbH was founded in February 2019 by Prof. Anke Schmeink from the Department of Information Theory and Systematic Design of Communication Systems, Prof. Guido Dartmann from the Institute for Communication Technologies and Embedded Systems and Dr. med. Lukas Martin and Prof. Gernot Marx from Uniklinik RWTH Aachen together with Prof. Christoph Thiemermann from the William Harvey Research Institute at Queen Mary University of London. Since then, the founding team has not only won the RWTH Spin-off Award 2019, but has also received funding of 1.6 million euros, including the EIT Health Headstart Award 2019 from the renowned European Institute of Innovation and Technology, and is now an exclusive partner of well-known companies (e.g. Microsoft, NVIDIA, Google).

As one of more than ten spin-offs from Uniklinik RWTH Aachen, Clinomic is part of the long success story of research transfer projects in the medical field. Nevertheless, he was particularly impressed by this founding team, said Prof. Marx, holder of Germany's only chair of anesthesiology with a research focus on operative intensive care medicine. "They are committed and courageous - at their age I hadn't even thought of the idea of founding.”

We are pleased to be part of the successful research transfer of Clinomic GmbH by supporting the conclusion of a licensing agreement and are excited to see how the young spin-off actively shapes the future of medical care and improves the treatment of patients in the long-term.

More About Clinomic.

Click here for start-up support for RWTH researchers.

Jörg von Appen
Jörg von Appen Dr. rer. nat.

Managing Director

+49 241 80 96608